Johnson & Johnson (NYSE:JNJ) Shares Purchased by Core Wealth Partners LLC

Core Wealth Partners LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.0% in the third quarter, Holdings Channel reports. The institutional investor owned 13,839 shares of the company’s stock after purchasing an additional 1,702 shares during the period. Johnson & Johnson makes up 1.4% of Core Wealth Partners LLC’s holdings, making the stock its 15th biggest holding. Core Wealth Partners LLC’s holdings in Johnson & Johnson were worth $2,243,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Johnson & Johnson in the first quarter worth approximately $765,000. Empowered Funds LLC increased its holdings in shares of Johnson & Johnson by 46.7% in the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after buying an additional 32,244 shares in the last quarter. Equity Investment Corp increased its holdings in shares of Johnson & Johnson by 6.0% in the first quarter. Equity Investment Corp now owns 88,922 shares of the company’s stock valued at $14,067,000 after buying an additional 4,998 shares in the last quarter. Zevenbergen Capital Investments LLC increased its holdings in shares of Johnson & Johnson by 3.5% in the first quarter. Zevenbergen Capital Investments LLC now owns 14,894 shares of the company’s stock valued at $2,356,000 after buying an additional 500 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. increased its holdings in shares of Johnson & Johnson by 16.7% in the first quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 21,000 shares of the company’s stock valued at $3,322,000 after buying an additional 3,000 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.3 %

JNJ stock opened at $155.05 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a market cap of $373.30 billion, a PE ratio of 22.44, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. The business’s 50-day simple moving average is $162.61 and its 200 day simple moving average is $155.91. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the business earned $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analyst Weigh In

Several research firms have issued reports on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. The Goldman Sachs Group reduced their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, TD Cowen lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.